Filtered By:
Infectious Disease: Hepatitis
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 271 results found since Jan 2013.
Cigarette smoke attenuates mesenchymal stem cell-based suppression of immune cell-driven acute liver failure
Toxicol Lett. 2023 Aug 10:S0378-4274(23)00242-4. doi: 10.1016/j.toxlet.2023.08.006. Online ahead of print.ABSTRACTDetrimental effects of smoking on mesenchymal stem cell (MSC)-dependent immunosuppression and hepatoprotection are unknown. Herewith, by using α-galactosylceramide (α-GalCer)-induced liver injury, a well-established murine model of fulminant hepatitis, we examined molecular mechanisms which were responsible for negative effects of cigarette smoke on MSC-dependent immunomodulation. MSC which were grown in cigarette smoke-exposed medium (MSCWS-CM) obtained pro-inflammatory phenotype, were not able to optimally ...
Source: Toxicology Letters - August 12, 2023 Category: Toxicology Authors: Dragica Pavlovic Dragana Miloradovic Milica Dimitrijevic Stojanovic Carl Randall Harrell Riccardo Polosa Sonja Rust Giovanni Li Volti Massimo Caruso Vladimir Jakovljevic Valentin Djonov Vladislav Volarevic Source Type: research
Biomaterial-based delivery platforms for transdermal immunotherapy
Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print.ABSTRACTNowadays, immunotherapy is one of the most essential treatments for various diseases and a broad spectrum of disorders are assumed to be treated by altering the function of the immune system. For this reason, immunotherapy has attracted a great deal of attention and numerous studies on different approaches for immunotherapies have been investigated, using multiple biomaterials and carriers, from nanoparticles (NPs) to microneedles (MNs). In this review, the immunotherapy strategies, biomaterials, devices, and disea...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 29, 2023 Category: Drugs & Pharmacology Authors: Mohammad Dahri Nima Beheshtizadeh Nasrin Seyedpour Amin Nakhostin-Ansari Faezeh Aghajani Simin Seyedpour Moein Masjedi Fatemeh Farjadian Reza Maleki Khosro Adibkia Source Type: research
Single-cell analysis reveals HBV-specific PD-1 < sup > + < /sup > CD8 < sup > + < /sup > TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients
J Exp Clin Cancer Res. 2023 Jun 23;42(1):152. doi: 10.1186/s13046-023-02710-4.ABSTRACTImmune checkpoint blockade (ICB) treatment of hepatocellular carcinoma (HCC) patients with hepatitis B virus (HBV) infection may activate viral-specific T cells to attack HBV infected hepatocytes and thus induce immune-related liver injury. Therefore, it is important to deeply understand the impacts of HBV infection on HCC immune microenvironment in order to better design effective immunotherapies for HBV+ (HBV infected) HCC patients. Here, We performed cytometry by time-of-flight (CyTOF) analyses to characterize the distinct immune compo...
Source: Cell Research - June 23, 2023 Category: Cytology Authors: Lulu Liu Junwei Liu Pan Li Jijun Luo Rui Qin Qiao Peng Bin Li Xuyong Wei Tian Wang Hongyu Shi Ming-Da Wang Chao Li Weijia Fang Wei Chen Xiao Xu Tian Yang Weiwei Yin Xun Zeng Source Type: research
Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model
CONCLUSION: In conclusion, these results suggest that PD-L1, CD86, and CD206 may be involved not only in the occurrence and development of HCC, but also in immune regulation, indicating the potential role of PD-L1 and CD86 as potential biomarkers and new therapeutic targets for prognosis assessment of liver cancer.PMID:37306737 | DOI:10.1007/s00432-023-04949-y
Source: Cell Research - June 12, 2023 Category: Cytology Authors: Panpan Kong Huan Yang Qing Tong Xiaogang Dong Mamumaimaitijiang-Abula Yi Dong Yan Source Type: research
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research
CONCLUSION: Patients with brain metastases, prior or concurrent malignancies, HIV infection, HBV/HCV infection, or low-functioning PS were overly restricted from participating in advanced prostate clinical trials. Advocating for broader criteria may ameliorate generalizability.PMID:37301665 | DOI:10.1016/j.clgc.2023.05.013
Source: Clinical Prostate Cancer - June 10, 2023 Category: Cancer & Oncology Authors: Hedyeh Ebrahimi Daniela V Castro Matthew I Feng Sweta R Prajapati Kyle O Lee Elyse H Chan Trishita Paul Ishaan Sehgal Jalen Patel Xiaochan Li Zeynep B Zengin Luis Meza Benjamin D Mercier JoAnn Hsu Ameish Govindarajan Neal Chawla Nazli Dizman Cristiane D B Source Type: research
Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis
CONCLUSION: IN is an efficacious and safer treatment option for MBM patients, especially for asymptomatic and treatment naïve patients.PMID:37228242 | DOI:10.1080/08923973.2023.2215403
Source: Immunopharmacology and Immunotoxicology - May 25, 2023 Category: Allergy & Immunology Authors: Mengmeng Su Yuyan Yang Peng Wang Source Type: research
